Article Sidebar
Published:
Jun 25, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Efficacy of diterpene ginkgolide meglumine injection in convalescent cerebral infarction and hemorheology
Abstract
Purpose: To investigate the effect of diterpene ginkgolide meglumine injection (DGMI) compared to betahistine in convalescent cerebral infarction (CI).
Methods: 80 convalescent patients with CI from March 2021 and March 2022 were randomly grouped into control and study groups comprising 40 participants each. Control and study groups received 20 mg betahistine and 25 mg DGMI respectively in 250 mL normal saline for 1 week. The efficacy, National Institute of Health Stroke Scale (NIHSS) score, hemorheology, and adverse effects were investigated in control and study groups
Results: Total effective rate was significantly higher in study group compared to control group (p < 0.05). Also, the National Institute of Health Stroke Scale (NIHSS) score, plasma viscosity (PV), whole blood reduced viscosity, fibrinogen (FIB), erythrocyte aggregation index (EAI), and incidence of adverse effect were significantly lower in study group compared to control group (p < 0.05).
Conclusion: Administration of DGMI to patients in the recovery period of CI improves neurological deficit, and average blood flow velocity in the brain, and reduces the incidence of adverse effects. Further studies with larger sample sizes and multi-center approaches will be required to validate these findings.
